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Abstract
Background: Hypoxia-inducible factors (HIFs) are well-established mediators of tumor growth, the epithelial to
mesenchymal transition (EMT) and metastasis. In several types of solid tumors, including breast cancers, the HIFs
play a critical role in maintaining cancer stem cell (CSC) activity. Thus, we hypothesized that HIFs may also regulate
transcription of markers of breast CSC activity. One approach to enrich for breast cells with stem-like phenotypes is
FACS sorting, in which sub-populations of live cells are gated based on the expression of cell surface antigens,
including various integrin subunits. Integrin alpha 6 (ITGA6; CD49f) is routinely used in combination with other
integrin subunits to enrich for breast stem cells by FACS. Integrins not only mediate interactions with the extracellular
matrix (ECM), but also drive intracellular signaling events that communicate from the tumor microenvironment to
inside of the tumor cell to alter phenotypes including migration and invasion.
Methods: We used two models of metastatic breast cancer (MBC), polyoma middle T (MMTV-PyMT) and MDA-MB-231
cells, to compare the expression of ITGA6 in wild type and knockout (KO) or knockdown cells. Chromatin
immunoprecipitation (ChIP) and luciferase reporter assays verified that ITGA6 is a direct HIF transcriptional target. We
also used FACS sorting to enrich for CD49f + cells to compare tumorsphere formation, tumor initiating cell activity,
invasion and HIF activity relative to CD49fneg or low cells. Knockdown of ITGA6 significantly reduced invasion, whereas
re-expression of ITGA6 in the context of HIF knockdown partially rescued invasion. A search of public databases also
revealed that ITGA6 expression is an independent prognostic factor of survival in breast cancer patients.
Results: We report that ITGA6 is a HIF-dependent target gene and that high ITGA6 expression enhances invasion and
tumor-initiating cell activities in models of MBC. Moreover, cells that express high levels of ITGA6 are enriched for HIF-
1α expression and the expression of HIF-dependent target genes.
Conclusions: Our data suggest that HIF-dependent regulation of ITGA6 is one mechanism by which sorting for CD49f
+ cells enhances CSC and metastatic phenotypes in breast cancers. Our results are particularly relevant to basal-like
breast cancers which express higher levels of the HIFα subunits, core HIF-dependent target genes and ITGA6 relative to
other molecular subtypes.
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Background
The rate of rapidly dividing cancer cells in solid tumors
quickly surpasses the rate at which new functional blood
vessels are formed. In these nutrient- and oxygen-
depleted areas, a hypoxic transcriptional response is or-
chestrated by the Hypoxia-Inducible Factor transcription
factors (HIFs), which mediate transcription of multiple
genes necessary to adapt to an adverse tumor micro-
environment [1]. Most solid tumors overexpress HIF-1α
and/or HIF-2α, and over-expression of HIF-1α inde-
pendently positively correlates with poor prognosis and
relapse of breast cancer patients, as reviewed in [2]. We
have shown using the mouse mammary tumor virus
(MMTV) driven- polyoma virus middle T transgenic
mouse model (PyMT) of metastatic breast cancer
(MBC) that conditional deletion of Hif1a delays onset of
palpable tumors, and reduces primary tumor growth
rate, lung colonization and overall metastatic burden [3].
Moreover, deletion of Hif1a reduces tumor-initiating cell
(TIC) frequency and activity in vivo [3]. Therefore, HIF-
1 regulates breast tumor growth and metastasis in part
by modulating pathways that promote cancer stem cell
(CSC)-like activities.
The CSC hypothesis postulates that tumors arise from
a small population of cancer cells with stem cell-like
properties [4], with a corollary that CSC-like cells play a
primary role in relapse due to therapeutic resistance
and/or enhanced metastatic potential [5]. Several labora-
tories have shown that the HIFs play a fundamental role
in maintaining CSC potential or a CSC niche in gliomas,
neuroblastomas, breast cancers, and hematological ma-
lignancies [3, 6–8]. A common feature of hypoxic cells
and CSC-like cells is that they are highly refractory to
radiation and chemotherapy [9, 10]. For example, hyp-
oxic regions of breast tumors that reappear after treat-
ment of the primary tumor with anti-angiogeneic
therapies are enriched with CSC-like cells [11]. Because
the HIFs are critical for maintaining CSC/TIC activity in
a variety of solid tumors, we hypothesized that HIFs may
also regulate transcription of markers used to enrich for
CSC-like cells.
Antibodies to integrin subunits that function as het-
erodimeric receptors for extracellular matrix (ECM) pro-
teins are routinely employed to enrich for normal
mammary stem cells and breast CSCs by fluorescence
activated cell sorting (FACS). These include integrin beta
1 (ITGB1; CD29), integrin beta 3 (ITGB3; CD61) and in-
tegrin α6 (ITGA6; CD49f) [12]. For example, either the
CD49f+/CD24+ [13] or the CD49f+/EpCAM+ (epithelial
cell adhesion molecule) [14] sub-populations will enrich
for cells with luminal progenitor potential. In contrast,
the CD49fHigh/CD24− sub-population is enriched for
basal/mesenchymal phenotypes [14, 15]. Relative to the
normal breast tissue, the CD49fHigh/EpCAM+ sub-
population is enriched in tumors and is believed to mark
the lineage that is the origin of luminal breast cancers
[15, 16].
Integrins not only mediate interactions with the ECM,
but also drive intracellular signaling events that commu-
nicate from the tumor microenvironment to inside of
the tumor cell to alter migration and invasion. CD49f di-
merizes with integrin ß1 or ß4 (ITGB4; CD104) to form
either α6ß1 or α6ß4 heterodimers, which bind to lam-
inin, an abundant component of the breast ECM. In the
normal breast, α6ß1 is expressed in both the luminal
epithelium and myoepithelial cells, whereas α6ß4 is
expressed in the myoepithelial cells [17]. Both ß1 and ß4
are implicated in modulating breast tumorigenesis and
metastasis [17–19]. In MDA-MB-435 cells, survival
under hypoxic stress and metastatic potential depends
on expression of the α6ß1 integrin and HIF-1-dependent
secretion of VEGF [20], which is a direct HIF target
gene. The α6ß4 heterodimer has been shown to mediate
cancer cell motility and metastasis [21]. Breast CSC ac-
tivity was recently shown to depend upon which cyto-
plasmic domain splice isoform of ITGA6 (α6A or α6B)
dimerizes with integrin ß1. Cells possessing CSC activity,
which also have mesenchymal features, were found to
express α6Bß1 [22].
A direct contribution of ITGA6 to breast CSC or TIC
potential was shown in mammospheres derived from
MCF-7 cells, which express higher levels of CD49f relative
to bulk cells; knockdown of ITGA6 also blocked tumor
growth in vivo [23]. Relative to the normal mammary
gland, expression of ITGA6 is up-regulated ~4.0-fold in
MMTV-Neu tumors [24]. Increased CD49f immunoreac-
tivity in tumor specimens correlates with reduced survival
of breast cancer patients [25]. CD49f also enriches for
glioblastoma CSCs [26]. Despite accumulating evidence
that higher CD49f expression correlates with CSC activity
and decreased survival in several cancer types, little is
known about how ITGA6 gene expression is regulated.
Since ITGA6 expression and a HIF transcriptional core
gene signature are enriched in basal-like breast tumors
relative to luminal (ER+) tumors [15, 27–30], we sought
to determine if ITGA6 might also be a direct HIF target
gene.
Herein, we demonstrate that ITGA6 is a direct tran-
scriptional target of the HIF transcription factors.
ITGA6 expression decreases at the mRNA and protein
levels in HIF-1 knockout (KO) PyMT cells, or in re-
sponse to knockdown of both HIF1A and HIF2A in
MDA-MB-231 cells. Three putative hypoxia response el-
ements (HREs) were identified in the ITGA6 promoter,
two of which efficiently bind either HIF-1α or HIF-2α.
Enriching for CD49f+ PyMT cells enhanced TIC poten-
tial as assayed by limiting dilution transplantation. Like-
wise, enriching for a CD49fHigh sub-population in MDA-
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MB-231 cells potentiated cell invasion through Matrigel
and HIF-dependent gene expression. The reduced
tumor-initiating and invasive potential in the CD49fNeg/
Low PyMT or MDA-MB-231 cells overlaps with pheno-
types in Hif1a null PyMT tumors [3] or HIF1A knock-
down in MDA-MB-231 tumor cells [31]. Together, these
results suggest that HIF-dependent transcriptional regu-
lation of ITGA6/CD49f contributes to the HIFs promo-
tion of TIC and invasion activity.
Results
Deletion of HIF reduces ITGA6 expression in PyMT tumor
cells
Itga6 mRNA levels were compared in HIF-1 wild type
(WT) and knockout (KO) PyMT tumor cells cultured
at normoxia or hypoxia by quantitative real-time PCR
(qRT-PCR). Itga6 mRNA levels increased 2-fold in
hypoxic WT cells relative to normoxic WT cells,
whereas Itga6 mRNA levels were decreased by ~50 %
in KO cells relative to WT cells at hypoxia (Fig. 1a).
Western blotting of whole cell extracts (WCE) con-
firmed that ITGA6 levels were decreased in HIF-1
KO cells relative to WT cells, independent of oxygen
tension (Fig. 1b). These results are consistent with
our previous observations that PyMT tumor cells ex-
press detectable levels of HIF-1α protein at normoxia,
although maximal levels of HIF-1α protein accumu-
late at 6 h of hypoxia (0.5 % O2) [3]. Similarly,
CD49f-FITC immunofluorescence (IF) staining of
fixed PyMT cells revealed a decrease in the total
number of CD49f + HIF-1 KO cells relative to WT
cells. No striking differences in CD49f staining
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Fig. 1 Itga6 expression is down-regulated in response to deletion of HIF-1 in PyMT+ cultured cells and in tumors. a HIF-1 WT or KO cells were
cultured at normoxia or hypoxia (6 h, 0.5 % O2) and the relative expression of Itga6 mRNA levels compared after normalization to Ints3. The mean
fold-change in Itga6 levels was compared to KO cells cultured at hypoxia (set to 1.0) (*p < 0.01, ANOVA with Bonferroni post-test; n = 3 biological
replicates). b Western blotting was performed for ITGA6 protein using whole cell extracts (WCE) prepared from near confluent HIF-1 WT and KO
cells cultured at either normoxia (N) or hypoxia (H). Tata-binding protein (TBP) is shown as a loading control. c HIF-1 WT and KO adherent cells were
exposed to normoxia or hypoxia (6 h, 0.5 % O2), fixed, immunostained with CD49f-FITC and counterstained with DAPI; the scale bar represents 20 μm.
d The relative abundance of Itga6 mRNA after normalization to Ints3 in the same set of HIF-1α WT and KO tumors as subjected to FACS analysis in
panel (e) (p < 0.01, Student’s t-test). e Representative histograms derived from FACS analysis of live, CD49-FITC stained cells isolated from HIF-1 WT
(black histogram) and KO (blue histogram) tumors relative to the isotype antibody control (red histogram). To normalize the histogram height between
samples, the y-axis shows the % Max (the number of cells in each bin divided by the number of cells in the bin that contains the largest number of
cells). Data shown are representative of n ≥5 tumors/genotype. The percentage of tumor cells positive for CD49f-FITC was determined based on the
live, singlet, Linneg parent population using FlowJo and the gating strategy presented in Additional file 4: Figure S4. f The mean ± SEM in the fold
change of CD49f-FITC median fluorescence intensity (MFI) between WT and KO PyMT tumors; all data are expressed relative to each genotype’s
corresponding isotype control MFI (p < 0.01, Student’s t-test; n ≥5 tumors/genotype)
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intensity were observed between normoxia and hyp-
oxic conditions for either genotype (Fig. 1c).
To confirm that CD49f is differentially expressed in
vivo, PyMT HIF-1 WT or KO cells were implanted into
the mammary fat pad of syngeneic FVB female recipi-
ents to generate tumors. Mean Itga6 mRNA levels were
reduced by ~50 % in KO tumors relative to WT (Fig. 1d).
When tumors were digested and single cells stained with
CD49f-FITC and subjected to FACS profiling (n ≥5 tu-
mors/genotype), the total percentage of CD49f+ cells
was decreased in HIF-1 KO tumors (Fig. 1e). The aver-
age CD49f-FITC median fluorescence intensity (MFI)
was also reduced ~1.5-fold in KO tumors relative to WT
(Fig. 1f ). These results suggested that HIF-1 regulates
ITGA6 gene expression and that the relative changes in
mRNA abundance are generally conserved at the protein
level.
Both HIF-1 and HIF-2 regulate expression of ITGA6 in
MDA-MB-231 breast cancer cells
We next investigated whether HIFs also regulate ITGA6
levels in a MBC cell line of human origin, MDA-MB-231.
The MDA-MB-231 cell line models basal/mesenchymal
breast cancer, and by molecular profiling is classified as a
basal B and claudin-lo subtype [15, 32–34]. MDA-MB-
231 cells have been characterized as CD49f+/CD24Neg and
by FACS up to 99 % of cells are CD49f + with a 2-log10
range of expression levels [15]. In MDA-MB-231 cells,
high levels of HIF-1α protein are present at normoxia, and
there are modest effects of hypoxic exposure on HIF-1 α
protein levels; in contrast, expression of HIF-2α is strongly
hypoxia-inducible (Additional file 1: Figure S1c). The ef-
fect of shRNA-mediated down-regulation of HIF1A alone,
HIF2A alone or both HIFα subunits (shHIF1A/shHIF2A)
on ITGA6 mRNA levels was compared relative to empty
vector transduced cells (referred herein as shControl) cul-
tured at normoxia or hypoxia (0.5 % O2; 6 h, “acute” or
24 h, “chronic”). Hypoxic exposure did not significantly
increase ITGA6 mRNA expression levels in shControl
cells (Fig. 2a). Likewise, deletion of either HIF1A
(shHIF1A) or HIF2A (shHIF2A) alone was not sufficient
to significantly reduce ITGA6 levels relative to shControl
cells. However, when HIF1A and HIF2A were simultan-
eously knocked down, a 2- to 3-fold decrease in ITGA6
expression was observed (shHIF1A/shHIF2A, Fig. 2a). As
previously reported, we observed that hypoxic exposure
represses transcription of HIF1A, but stimulates transcrip-
tion of HIF2A [35] (Additional file 1: Figure S1a, b).
shRNA knockdown was not 100 % efficient for either gene
as we previously described in [36]. Detectable levels of
HIF-1α or HIF-2 α protein were observed in shHIF1A,
shHIF2A and shHIF1A/shHIF2A cells, and individual
gene knockdown was generally less efficient under
hypoxic stress than during normoxic culture (Additional
file 1: Figure 1c).
Changes in ITGA6 mRNA expression were next verified
at the protein level. By western blotting, ITGA6 protein
levels were reduced in shHIF1A/shHIF2A cells relative to
shControl cells in a HIF-dependent, but hypoxia-
independent manner (Fig. 2b). IF staining of MDA-MB-
231 adherent cells revealed that almost all shControl cells
express CD49f. In contrast, there was a reduction in
CD49f-FITC staining in both shHIF1A and shHIF1A/
shHIF2A cells relative to shControl cells, whereas more
subtle reductions in CD49f intensity were noted for
shHIF2A cells (Fig. 2c). In agreement with western blot
data, by FACS analysis, the percentage of CD49f-FITC+
cells present in each genotype of MDA-MB-231 cells did
not significantly change in response to hypoxic exposure
(Fig. 2d). FACS analysis revealed no statistically significant
differences in the total percentage of CD49f + cells in re-
sponse to either HIF1A or HIF2A deletion, although there
was general trend of fewer CD49f + cells in the shHIF1A
genotype that was not observed for shHIF2A cells. Inde-
pendent of oxygen tension, the shHIF1A/shHIF2A cells
consistently exhibited a ~3-to-4-fold decrease in the total
percentage of CD49f+ cells relative to shControl cells
(Fig. 2d).
Comparison of the average CD49f MFI among 5 inde-
pendent FACS experiments revealed that the fluorescent
intensity was only significantly reduced when both HIFs
were knocked down (Fig. 2e, ~2.3 fold), although there
was also trend for a reduction in the MFI in shHIF1A,
but not shHIF2A, cells. Together, these results demon-
strate that CD49f expression is more dependent upon
HIF activity than oxygen tension per se. A similar reduc-
tion in percentage of cells staining positive for CD49f-
FITC in response to deletion of both HIFα subunits was
also observed in MCF-7 cells, a luminal model of breast
cancer in which ~10 % of all cells express CD49f [15]
(~3-fold decrease for shControl vs. DKD cells; Add-
itional file 2: Figure S2). Finally, qRT-PCR analysis of
shControl, shHIF1A, shHIF2A or shHIF1A/shHIF2A
MDA-MB-231 whole tumors generated in [36] revealed
that ITGA6 levels were significantly decreased upon
knockdown of either HIF1A or both HIFα subunits. How-
ever, there was no change in ITGA6 expression in
shHIF2A tumors (Fig. 2f). These data suggest that HIF-1
may be predominantly responsible for ITGA6 expression
and that HIF-2 can compensate for loss of HIF-1 activity.
ITGA6 is a direct HIF transcriptional target gene
Based on the observed HIF-dependent regulation of
ITGA6 mRNA levels and of CD49f cell surface expres-
sion in PyMT, MDA-MB-231 and MCF-7 tumor cells,
we next investigated whether ITGA6 is a direct HIF
transcriptional target. Three consensus putative hypoxia
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response elements (HREs) were identified in the human
ITGA6 promoter (Fig. 3a), located at −170, −1333, and
−1762 from the transcriptional start site. A presumably
conserved HRE site was also identified in the murine
Itga6 promoter at −1690.
Chromatin immunoprecipitation (ChIP) assays were
performed using MDA-MB-231 shControl or shHIF1A
knockdown cells (to control for HIF-1α antibody specifi-
city). All cells used for ChIP analysis were cultured at
acute hypoxia (6 h, 0.5 % O2) since HIF-1α protein levels
peak at this time point [36]. HIF-1α was recruited to
both the −170 and −1762 HRE sites in shControl cells
(Fig. 3b), with a mean site fold enrichment of 4.2-fold or
3.8-fold, respectively (Fig. 3b). A previously validated
functional HRE present in the 3’ UTR of the EPO en-
hancer [37] served as the assay positive control (Fig. 3b).
In contrast, there was weak enrichment of HIF-1α at the
−1333 site in shControl cells relative to shHIF1A cells
(Additional file 3: Figure S3A). There was no significant
difference in enrichment of either HIF-1α or HIF-2α to
a non-HRE site in the promoter (Additional file 3: Figure
S3B). Enrichment of HIF-1α at the −1690 site of the
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Fig. 2 ITGA6/CD49f expression is reduced in response to loss of HIF activity in MDA-MB-231 cells and tumors. a Mean ± SEM of the expression of
ITGA6 mRNA relative to PPIA, in adherent, cultured MDA-MB-231 cells (n = 3 independent biological experiments/genotype). mRNA levels were
evaluated after 0, 6 or 24 h of hypoxic exposure. All data are expressed relative to shControl cells cultured at normoxia (set to 1.0); *p-value <0.05
by ANOVA. b Western blotting was performed for ITGA6 protein using whole cell extracts (WCE) prepared from near confluent MDA-MB-231
shControl or shHIF1A/shHIF2A cells cultured at either normoxia (N) or chronic hypoxia (H). Tata-binding protein (TBP) is shown as a loading
control. c MDA-MB-231 shControl, shHIF1A, shHIF2A and shHIF1A/shHIF2A cells were harvested from normoxic cell culture at 90 % confluence, stained
with CD49f-FITC in suspension, replated onto chamber well slides and stained with Hoechst 33342; scale bar represents 20 μM. d MDA-
MB-231 shControl, shHIF1A, shHIF2A and shHIF1A/shHIF2A cells were harvested from normoxic or chronic hypoxic cell culture at 90 % confluence,
stained with CD49f-FITC in suspension in flow buffer, and subjected to FACS analysis. Plots represent the % Max of stained cells (red histogram) versus
the corresponding genotype’s isotype control (blue histogram); data presented are representative of 4 biological replicate experiments. e The average
± SEM in the fold change (FC) in the CD49f MFI among all four genotypes of cultured cells (n = 4 independent experiments/genotype; shControl set
to 1.0; p <0.05.). f The average ± SEM in the fold change (FC) of ITGA6 mRNA levels expressed in tumors among all four genotypes (n = 4 tumors/geno-
type; shControl set to 1.0; p <0.05.); total RNA was prepared from homogenized whole tumors
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murine Itga6 promoter in PyMT WT cells relative to
HIF-1 KO cells was also confirmed (Additional file 3:
Figure S3C).
Since we previously reported that HIF-2α protein ex-
pression increases in response to HIF1A shRNA-
mediated gene knockdown in both MCF-7 cells [38] and
MDA-MB-231 cells [36], we next investigated if HIF-2α
expression could compensate for loss of HIF-1α to regu-
late ITGA6 transcription in MDA-MB-231 cells. ChIP
assays were repeated for the same HRE sites using anti-
HIF-2α antibodies. HIF-2α bound more efficiently to the
−170 and the −1762 sites in shHIF1A cells relative to
shControl cells (Fig. 3b). Likewise, HRE site enrichment
in the EPO 3’ UTR was increased in shHIF1A cells fol-
lowing IP with HIF-2α (Fig. 3b). These results demon-
strate that, in MDA-MB-231 cells, either HIF-1α or
HIF-2α can potentiate ITGA6 transcription, as suggested
by the expression data presented in Fig. 2.
To confirm the functionality of bound HIF-α subunits
to the ITGA6 promoter, luciferase (Luc) reporter assays
were employed. An ITGA6-Luc reporter vector was pur-
chased from SwitchGear that contained the most prox-
imal HRE site validated by ChIP assays, and the HRE
consensus site was mutated (ITGA6-mutant-Luc). Rela-
tive luciferase activity was measured in the presence or
absence of ectopic expression of a stabilized murine
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Fig. 3 ITGA6 is a direct HIF transcriptional target gene. a A schematic representation of putative HREs identified in the proximal promoter of
ITGA6 that were assessed for HIF-1α and/or HIF-2α recruitment by ChIP assays. b MDA-MB-231 shControl and shHIF1A cells were cultured at hypoxia
(0.5 % O2) for 6 h, and chromatin fragments were immunoprecipitated using HIF-1α or HIF-2α antibodies or anti-rabbit IgG (as the non-specific binding
control). SYBR Green-based qRT-PCR was conducted on the purified, isolated DNA fragments to determine the site fold enrichment of HIFα recruitment
relative to signal detected in the anti-rabbit IgG control per genotype (qRT-PCR values observed for the IgG control were set to 1.0 per genotype). As
the positive control, qRT-PCR was also performed using primers flanking a previously validated, functional HRE site in the 3’ EPO enhancer. Each panel
shows the mean site fold enrichment ± SEM of technical replicates; data presented are representative of three replicate experiments. c Luciferase
reporter assays were used to compare relative luciferase activity between MDA-MB-231 shControl or shHIF1A/shHIF2A cells transiently transfected with
a wild type ITGA6 promoter linked to luciferase (ITGA6-Luc; white bars) or a HRE mutant promoter construct [ITGA6 (mutant)-Luc; grey bars] and then
cultured at normoxia (Nor) or hypoxia (Hyp). In some cases, a stabilized version of murine HIF-1α was also co-transfected (+HIF1A). The mean
± standard deviation are shown; p <0.05 by one-way ANOVA followed by Bonferroni's multiple comparison test. The mutant ITGA6 promoter
contains three point mutations within the HIF consensus site
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HIF-1α mutant that cannot be degraded by the prote-
asome [39]. Although changes in reporter activity were
not observed in response to the endogenous changes in
HIFα levels between shControl and shHIF1A/shHIF2A
MDA-MB-231 cells, in the presence of transfected
mHIF-1α stabilized protein, luciferase activity increased
7.6-fold at normoxia and 10.8-fold at hypoxia relative to
shControl normoxic cells (Fig. 3c). Luciferase reporter
activity significantly decreased in ITGA6-mutant-Luc
transfected cells in the presence of ectopic mHIF-1α.
CD49f enrichment enhances sphere formation efficiency
and TIC activity in the PyMT model
To enrich for CD49f-FITC+ cells in PyMT tumors, individ-
ual tumors from transgenic females were combined and
digested to obtain a single cell preparation. Live, singlet,
Linneg/CD31neg tumor cells were sorted based on expres-
sion of CD49f and CD24. As we previously described, vir-
tually all cells derived from late stage PyMT carcinomas
express CD24 [3]. CD49f+/CD24High or CD49fNeg/CD24Low
cells were enriched in a two-way sort and purity was con-
firmed by post-sort analysis (refer to Additional file 4:
Figure S4).
Sorted cells were immediately plated into either tumor-
sphere formation assays in vitro or directly injected into
recipient FVB females in a limiting dilution transplant-
ation assay. The sphere formation efficiency (SFE) of
CD49f+/CD24High cells was ~3.5 times higher than ob-
served of CD49fNeg/CD24Low cells (Fig. 4a, p = 0.0001;
figure representative of three experiments). CD49f
+/CD24High cells also regenerated primary tumors that
were larger in volume at study endpoint than tumors de-
rived from CD49fNeg/CD24Low cells, regardless of initial
input cell number (Fig. 4b; n ≥ 6 recipient mice/sub-popu-
lation/cell density, also refer to Table 1). Overall, few palp-
able tumors were generated by the CD49fNeg/CD24Low
population (Fig. 4b; n = 2 tumors, 200 cells input; n = 1
tumor, 100 cells input; n = 1 tumor, 50 cells input; n = 0
tumors, 25 cells input). When TIC frequency was com-
pared by Extreme Limiting Dilution Analysis (ELDA) soft-
ware [40] at day 51 post-transplant, the frequency of TICs
in the CD49f+/CD24High population was significantly
higher than in the CD49fNeg/CD24Low population- 1 in 99
cells versus 1 in 578 cells, respectively (p = 0.00043)
(Table 1), an overall enrichment of 5.8-fold. These data
demonstrate that CD49f enriches for TIC potential in
vitro and in vivo in the PyMT model.
End-stage primary tumors derived from limiting dilution
transplantation were also harvested and digested to gener-
ate a single cell preparation for FACS analysis to compare
CD49f-FITC and CD24-PE expression in regenerated tu-
mors (Fig. 4c; data representative of n ≥5 tumors/sorted
population). We observed that all tumors derived from
CD49f+/CD24High cells were composed of 3 distinct cell
populations: a CD49f+/CD24High population (~51 %), a
CD49fNeg/CD24High population (~34 %), and a population
of CD49fNeg/CD24Low cells (~14 %). In contrast, none of
the tumors derived from CD49fNeg/CD24Low cells regener-
ated a CD49fNeg/CD24Low population, with cells almost
equally divided between the CD49f+/CD24High and the
CD49fNeg/CD24High quadrants. Therefore, CD49f
+/CD24High cells can regenerate both the cell population
of origin, and a CD49fNeg/CD24Low population.
Although these studies were not powered a priori to
compare lung metastases, metastatic burden was also
compared in a subset of mice that were implanted with
either 100 or 200 cells input and in which tumors were
allowed to grow to a volume of 500 mm3. At this tumor
volume, the lungs were harvested in conjunction with
the primary tumor. When scored for the total number of
lung lesions, more metastases were present in mice bear-
ing mammary tumors derived from CD49f+/CD24High
than CD49fNeg/CD24Low cells. These data were signifi-
cant for the 200-cell cohort, but did not reach statistical
significance for the 100-cell cohort (Fig. 4d).
ITGA6 is necessary for efficient invasion in MDA-MB-231
cells and ectopic expression can partially rescue invasion
of shHIF1A/shHIF2A cells
It is well-established that the HIFs are required to pro-
mote efficient invasion of breast cancer cells through
Matrigel in response to hypoxic stress in vitro, and are
essential in vivo for efficient lung metastasis from the
mammary gland or in tail vein assays [3, 41]. Because
CD49f expression is virtually eliminated in shHIF1A/
shHIF2A MDA-MB-231 cells, and since either HIF-1 or
HIF-2 can regulate transcription of ITGA6 (Fig. 3), we
first compared invasion of non-sorted shControl and
shHIF1A/shHIF2A cells cultured at normoxia or hyp-
oxia. No significant changes in the invasion index (cor-
rected for random migration) were observed at
normoxia, but invasion decreased by ~33 % in shHIF1A/
shHIF2A cells at hypoxia (Fig. 5a).
To determine if invasion requires ITGA6, ITGA6
mRNA was knocked down by transient transfection with
siRNAs in MDA-MB-231 cells; siRNA to GFP served as
the control. At normoxia, the mean invasion index was
reduced in ITGA6 siRNA cells by 60 %, and at hypoxia,
the mean invasion index was reduced by 67 %. In agree-
ment with our observations that ITGA6 expression is
dependent upon HIF activity, but not hypoxic stress
(Figs. 1 and 2), hypoxic exposure had no effect on inva-
sion of the ITGA6 siRNA cells, as there was no signifi-
cant difference in invasion between normoxia or hypoxia
(Fig. 5b). Since ITGA6 is only one of many HIF-
responsive target genes, we next tested whether ectopic
expression of ITGA6 in the shHIF1A/shHIF2A context
could rescue invasion potential. A stable shHIF1A/
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Table 1 ELDA analysis of TIC frequency at day 51 post-transplant for the CD49fNeg/CD24Low or CD49f+/CD24High sorted cell populations
isolated from MMTV-PyMT+ tumors that were implanted into the cleared mammary fat pad of recipient mice at low density; the number
of animals producing tumors/the number of animals transplanted is also indicated
Sorted population:
Number of cells injected: CD49fNeg/CD24Low CD49f+/CD24High p-value:
200 2/7 (29 %) 5/7 (71 %)
100 1/6 (17 %) 4/6 (67 %)
50 1/8 (12 %) 6/9 (67 %)
25 0/8 (0 %) 1/8 (12 %)
Estimated TIC Frequency 1/578 1/99
(95 % C.I.) (1/216 to 1/1,544) (1/58 to 1/170) 0.00043
D
CD49f+/CD24High CD49fNeg/CD24Low
CD49f+/
CD24High
CD49fNeg/
CD24Low
CD49f+/
CD24High
CD49f+/
CD24High
CD49fNeg/
CD24Low
CD49fNeg/
CD24Low
100 cells 200 cells
A B
C
Fig. 4 CD49f enriches for TIC activity in vitro and in vivo. a Tumors harvested from MMTV-PyMT+ females were harvest, digested, and stained with
CD49f-FITC and CD24-PE antibodies prior to FACS sorting. CD49f+/CD24High and CD49fNeg/CD24Low sorted cell populations were plated in sphere
culture conditions to assay for sphere formation efficiency (SFE), or were transplanted by limiting dilution transplantation into female FVB/Nj recipients.
a Each sorted cell population was plated at a density of 30,000 cells/well in 6-well format and the grand mean SFE ± SEM determined (n≥ 8 wells per
genotype; n = 3 independent experiments). The p-value was calculated by an unpaired Student’s t-test. b Comparison of changes in mean tumor
volume over time when 50, 100 or 200 CD49f+/CD24High or CD49fNeg/CD24Low sorted cells are transplanted into the cleared inguinal
mammary fat pad to assay for TIC potential. The number of tumors that formed for each cohort is indicated in Table 1. c CD49f/CD24
expression was analyzed by FACS analysis of end-stage tumors derived from the transplantation of CD49f+/CD24High or CD49fNeg/CD24Low sorted cells;
data are representative of n≥ 4 tumors/transplanted population. d Lung metastasis was evaluated in mice bearing tumors originating from CD49f
+/CD24High or CD49fNeg/CD24Low cell populations. A subset of mice in the 100-cell and 200-cell inputs were housed until tumors grew to a volume of
~500 mm3 at which time the tumors and lungs were harvested. The mean total number of lung metastases ± SEM present in H&E-stained paraffin
sections is shown in the box-and-whisker plot; *p <0.05 by Student’s t-test; N.S. equals not significant
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shHIF2A cell line was created expressing ITGA6, result-
ing in a 37 % percent increase in expression relative to
shHIF1A/shHIF2A cells (Additional file 5: Figure S5)
and invasion was compared at hypoxia. Although the ef-
fects on invasion were modest, re-expression of ITGA6
increased invasion in a statistically significant manner
relative to shHIF1A/shHIF2A cells (Fig. 5c).
Enrichment of invasion potential and HIF-dependent gene
expression in CD49f+ MDA-MB-231 cells
We next investigated whether metastatic potential is en-
hanced in MDA-MB-231 cells enriched for CD49f ex-
pression (CD49fHigh) when cultured at hypoxia. Cultured
shControl cells were gated for live, singlet cells and then
two-way sorted on the basis of CD49f-FITC levels into
either CD49fHigh or CD49fLow populations, representing
the upper or lower 20 % of singlet-gated cells (refer to
Additional file 6: Figure S6). Sorted cells were allowed to
recover overnight in stem cell media and were then
plated for invasion assays. We observed that the invasion
index was significantly higher in CD49fHigh cells relative
to either CD49fLow cells or to stained, but mock-sorted
cells (Mock; Fig. 6a).
A subset of sorted cells were also cytospun onto slides
and stained with HIF-1α antibodies, which revealed an
enrichment for HIF-1α protein in CD49fHigh cells rela-
tive to CD49Low cells (Fig. 6b). In contrast, no discern-
able differences in HIF-1α signal were observed between
mock-sorted and CD49fHigh cells, as might be expected
since ≥ 95 % of shControl cells stain with CD49f by
FACS analysis (Fig. 2d). The HIF-1α signal was predom-
inantly detected in the cytoplasm of MDA-MB-231 cells,
likely because the sorted cells were exposed to ambient
oxygen tensions during FACS sorting and during all
antibody incubations.
Expression levels of known HIF-dependent target genes
were next compared among the Mock-sorted, CD49fHigh
and CD49fLow cell populations by qRT-PCR (Fig. 6c). As
expected, ITGA6 mRNA levels were decreased in
CD49fLow cells and enriched in CD49fHigh cells relative to
Mock-sorted cells. Expression of prolyl hydroxylase 3
(PHD3), a gene predominantly regulated by HIF-1 rather
than HIF-2 in breast cancer cells [38], was enriched in
Normoxia Hypoxia
Hypoxia
p=0.01
p=0.001
shCon shHIF1A/
shHIF2A
+ pcDNA3
shHIF1A/
shHIF2A 
+ ITGA6
A B
C
Fig. 5 Manipulation of ITGA6 levels directly impacts invasion. a Non-sorted, cultured shControl or shHIF1A/shHIF2A MDA-MB-231 cells were evaluated
for invasive potential using Boyden chamber assays. The grand mean of the invasion index (invasion corrected for random migration) ± SEM
of 3 independent experiments is shown; p-values calculated by Student’s t-test are indicated. b Knockdown of ITGA6 impairs invasion at
normoxia and hypoxia. The grand mean of the invasion index (invasion corrected for random migration) ± SEM of 3 independent experiments is
shown; p-values were calculated by Student’s t-test. c Ectopic expression of ITGA6 in shHIF1A/shHIF2A cells partially rescues invasion at hypoxia. The
grand mean of the invasion index (invasion corrected for random migration) ± SEM of 3 independent experiments is shown; p-values were calculated
by Student’s t-test.
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CD49fHigh cells by ~2.5-fold. Carbonic anhydrase IX
(CAR9), which is also predominantly regulated by HIF-1
in breast cancer cells [38], was up-regulated in CD49fHigh
cells by >11-fold relative to Mock-sorted or CD49fLow
cells. Expression of Wnt-1-inducible signaling pathway
protein-2 (WISP2), a gene predominantly regulated by
HIF-2 than HIF-1 in breast cancer cells [38], was enriched
by >5.0 fold in CD49fHigh cells (Fig. 6c). These data dem-
onstrate that HIF-1α is functional and that hypoxic tran-
scriptional outputs are enriched in CD49fHigh relative to
CD49fLow MDA-MB-231 cells.
High expression levels of ITGA6 independently correlate
with survival of breast cancer patients
Breast cancers have been classified into five major sub-
types on the basis of global gene expression; one of sev-
eral genes up-regulated in basal-like cancers relative to
other subtypes is ITGA6 [27]. We first confirmed using
The Cancer Genome Atlas (TCGA) data [30] that
ITGA6 expression is enriched in basal-like breast can-
cers (Fig. 7a). A similar level of enrichment in basal-like
cancers was also detected in a second independent data-
set [42] [GEO: GSE1992; data not shown]. We next
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Fig. 6 Enriching for CD49f by cell sorting enhances cell invasion in MDA-MB-231 cells. a Mock-sorted, CD49fHigh or CD49fLow MDA-MB-231 cell
populations were exposed for 24–48 h to hypoxia and invasion then compared (n= 3-4 replicate wells/population/experiment; data are representative
of 3 independent sort experiments); p-values calculated by Student’s t-test are shown. The grand mean invasion index ± SEM is expressed relative to
Mock-sorted cells (cells stained with CD49f-FITC but not gated during sort; set to 1.0). b IF staining for CD49f-FITC and HIF-1α in cytospun CD49fHigh,
CD49fLow or Mock sorted cells counterstained with DAPI; scale bar = 50 μm. c qRT-PCR analysis to compare expression levels of known HIF-dependent
target genes in the CD49fHigh vs. CD49fLow cell populations; all values were first normalized for loading and were then normalized to Mock sorted cells
(white bars; fold change, FC set to 1.0). The mean ± SEM is reported for three independent experiments
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queried if expression of ITGA6 correlated with HIF1A or
HIF2A mRNA levels in the TCGA dataset. A small, but
statistically significant, positive correlation was observed
between HIF1A and ITGA6 expression in the TCGA
samples (r2 0.0078, p < 0.05). In contrast, no correlation
was observed between ITGA6 and HIF2A expression
(Fig. 7b). When patient samples were stratified by the
highest and lowest quartiles of tumor ITGA6 expression
[GEO: GSE1992], higher levels of ITGA6 expression pre-
dicted significantly shorter overall survival (OS; Fig. 7c)
and recurrence-free survival (RFS; Fig. 7d) as compared
to patients with low ITGA6 expression.
Discussion
The molecular networks that promote metastasis down-
stream of HIF are not yet fully elucidated. Likewise, the
mechanisms by which enriching for CD49f selects for cells
with stem-like activities in breast or other cancers, includ-
ing prostate [43] and glioblastoma [26], are poorly
understood. We have demonstrated using two models of
metastatic breast cancer that ITGA6 is a HIF-dependent
transcriptional target gene. Our data suggest that ITGA6
is regulated in a HIF-dependent, but oxygen-tension inde-
pendent manner and that ITGA6 expression can be regu-
lated by HIF-2 when HIF-1α levels are reduced. This
mode of regulation is in agreement with our previous ob-
servations that the individual HIFα isoforms tend to
modulate the kinetics of target gene expression rather
than specific sets of gene targets [38]. One caveat of our
study is that the shRNAs employed to knockdown HIF1A
and HIF2A did not completely eradicate HIFα protein ex-
pression under hypoxic stress, although few shRNAs tar-
get with 100 % efficiency. Future studies employing
CRISPR/Cas9 mediated gene editing to create efficient
knockout lines may be useful to test the requirement for
HIF-1 vs. HIF-2 in the regulation of ITGA6 expression.
We propose that ITGA6 functions as one key medi-
ator of the well-characterized HIF-dependent promotion
p < 0.05
r2 = 0.0078
TCGATCGA
p = 0.08
TCGA
CD49f High
CD49f Low
p < 0.05
CD49f High
CD49f Low
p < 0.05
D
A
C
B
Fig. 7 ITGA6 expression levels are prognostic of overall or recurrence-free survival of breast cancer patients. a ITGA6 mRNA is differentially expressed in
human breast cancers classified by the PAM50 subtype in the TCGA data set [30]; ***p < 0.001, ANOVA with Bonferroni post-test; (n = 93 basal, 56 HER2
+, 228 Luminal A, 123 Luminal B and 7 normal-like tumors). b ITGA6 mRNA levels also weakly positively correlate with HIF1A levels (p <0.05, correlation
coefficient r2 = 0.0078; TCGA data), but not with HIF2A mRNA levels (p = 0.08). c-d Kaplan-Meier curves depict the probability of overall survival (c) or
recurrence-free survival (d) based on relative ITGA6 mRNA expression from clinical data reported in [42]. ITGA6 expression levels were stratified by the
upper quartile or lowest quartiles (n = 37 tumors for “High” CD49f expression, and n = 45 tumors for “Low CD49f”) and significance determined by the
log-rank test, *p < 0.05)
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of CSC/TIC and metastatic activities [8, 44]. This is
based on our observations using in vivo samples that
loss of HIFα subunits reduces ITGA6 mRNA expression
and that enriching for CD49f+ in PyMT cells enhances
tumorsphere formation, tumor initiation and lung me-
tastasis. Our results support previous studies describing
a positive, direct relationship between ITGA6 levels and
metastatic potential using a panel of breast cancer cell
lines, including MDA-MB-231 cells [45]. Of note, an in-
verse relationship between ITGA6 mRNA and estrogen
receptor (ER) mRNA levels was identified in this study,
prior to the discovery that ITGA6 mRNA is a marker of
the basal-like breast cancer subtype [27]. Moreover, the
presence of EpCAM-/CD49f + cells has recently been
shown to increase metastatic potential and to reduce
disease-free survival of breast cancer patients [46];
MDA-MB-231 cells are classified as EpCAM−/CD49f
+ [15].
Increasing evidence supports observations that the re-
lationship between HIF activity and CD49f expression is
more prominent in basal breast cancers as compared to
luminal cancers. First, a HIF transcriptional core gene
signature is significantly enriched in basal breast cancers
[29, 30]. Second, we have shown that HIF-1α and HIF-
2α protein levels are enriched in basal breast cancers
relative to luminal tumors [36]. We also confirm herein
that ITGA6 expression is an independent prognostic fac-
tor of RFS and OS in breast cancer patients, as was sug-
gested in [25] and was shown in [46]. Our results are
also similar to those of Ali et al., who found that increas-
ing levels of CD49f protein are prognostic of reduced
survival, but only in ER negative patients [47].
Several markers routinely used to enrich for breast
CSCs by FACS are regulated by hypoxia via HIF-1, in-
cluding heat stable antigen (CD44) and CD24 [48, 49].
The pairing of CD44 and CD24 was first employed to
select for TICs in solid tumors, leading to observations
that in breast cancer the CD44High/CD24Neg/Low sub-
population has enriched TIC activity [50]. In contrast, in
several transgenic mouse models of breast cancer, the
consensus is that the CD24+/High sub-population rather
than CD24Neg/Low sub-population enriches for TIC activ-
ities when CD24 is paired with either CD29 (ITGB1) or
CD61 (ITGB3) [51–53]. Hypoxia also regulates tran-
scription of Prominin-1 (PROM1; CD133) [54]. CD133
has been widely employed to enrich for CSCs in several
types of solid tumors. In particular, in patient-derived
xenografts, when combined with CD49f and CD44,
CD133 further enriches for cells with CSC activity, but
only in basal-like tumors [55, 56]. We previously identi-
fied CD133 as a HIF-dependent gene that, when com-
bined with CD24, enriches for tumorsphere formation in
the PyMT model [3]. There are also an increasing num-
ber of direct connections between hypoxia and CSC
activity. Particularly germane to the oxygen tension fluc-
tuations typical of solid tumors, repeated exposure of
breast cancer cells to cycles of normoxic and hypoxic
conditions increases the frequency of CSCs, and leads to
a more aggressive phenotype [57].
Several studies have shown that enrichment for CD49f
+ cells enhances, but that loss of function represses,
tumorigenesis and metastasis phenotypes. For example,
Itga6 knockdown in 4T1 cells decreases metastasis [58].
In the Brca1 mutant mouse model, deletion of Itga6
alone, or along with CD29 significantly repressed metas-
tasis [59], and in the MMTV-Neu model, CD49f paired
with CD61 enriches for a sub-population of cells with
enhanced TIC potential [58]. In MCF-7 cells, CD49f en-
richment is sufficient to select for cells with enhanced
stem-like properties, including the ability to form mam-
mospheres in vitro and to more efficiently produce tu-
mors in vivo [23]. In a prostate cancer model, animals
with established bone metastasis that were treated with
blocking antibodies to CD49f exhibited decreased pro-
gression of osteolytic disease [60]. Therefore, high levels
of CD49f correlate with enhanced tumorigenesis and
metastasis phenotypes. Although fewer MCF-7 cells are
positive for CD49f relative to MDA-MB-231 or other
mesenchymal-like breast cancer cell lines [15], we ob-
served a conserved decrease in CD49f expression in
shHIF1A/shHIF2A MCF-7 cells.
We also find that the CD49fHigh MDA-MB-231 cells
express higher levels of HIF-1α protein and mRNAs of
known downstream HIF target genes relative to Mock-
sorted or CD49fLow cells. Therefore, we propose that
selecting for cells that express high levels of CD49f may
also co-select for cells with an enhanced hypoxic re-
sponse. CAR9, a surrogate marker of tumor hypoxia [61]
that promotes tumor growth and lung metastasis [62],
was highly enriched in CD49fHigh cells. However, unex-
pectedly based on the levels of HIF-1α immunostaining
observed in the sorted cell populations, CAR9 expression
was also enriched in CD49fLow cells relative to Mock
cells. It is possible that differences in HIF-2α protein
levels between Mock, CD49fLow and CD49fHigh cells may
also contribute to the gene expression changes we ob-
served in sorted cells since HIF-1 and HIF-2 often com-
pensate for each other to regulate transcription of target
genes [38]. CAR9 expression correlates independently
with OS in patients with invasive breast cancer [63] and
like, CD49f, CAR9 expression is highest in the basal sub-
type [64]. Moreover, loss of CAR9 represses breast CSC
activities and expression of genes involved in EMT and
maintaining stemness [65]. Another HIF-dependent tar-
get expressed at higher levels in CD49fHigh MDA-MB-
231 cells was PHD3; HIF activity is essential for PHD3
expression since deletion of HIF-1 and HIF-2 eliminates
PHD3 expression in breast cancer cells [38].
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In addition to their utility as an enrichment method to
capture cells with CSC activities, integrins are essential
for regulating invasion and migration of tumor cells dur-
ing metastasis [66]. Integrin function is crucial not only
for physically tethering cells to the matrix, but also for
sending and receiving molecular signals that regulate
these processes during tumorigenesis [67]. Integrins are
also involved in multiple points of the metastatic cas-
cade, including local invasion and growth in distant or-
gans. Yet, which transcription factors are required for
regulation of ITGA6 gene expression is poorly defined.
Functional Sp1/Sp3 sites in the promoter region have
been confirmed by ChIP analysis [68], and consensus
binding sites for NF-κB, AP-1 and Myc, were also identi-
fied [69]. A search of ChIP-seq data deposited into the
University of California Santa Cruz (UCSC) Genome
Browser by the Encyclopedia of DNA elements (EN-
CODE) consortia confirmed that Myc, which shares a
consensus binding elements with HIF-1, binds to the
ITGA6 promoter [ENCODE: ENCSR000DMQ]. Yet, in
MCF-7 cells, a ChIP-seq pipeline to identify HIF-1 and
HIF-2 binding sites did not reveal ITGA6 as a high strin-
gency HIF target [70]. It is possible that there are differ-
ences in DNA accessibility for HIF binding sites between
MDA-MB-231 and MCF-7 cells, or that the stringency
of the ChIP-seq data analysis pipeline described in [70]
excluded ITGA6. We recently validated breast tumor
kinase (BRK/PTK6) as a HIF-dependent gene highly
expressed in basal breast cancers [36]; however, PTK6
was also not identified as a HIF-dependent gene in this
ChIP-seq study [70].
At the post-translational level, chronic hypoxia in-
creases the cell surface localization of CD49f in a Rab11-
dependent manner, leading to increased α6ß4 at the cell
membrane and increased invasion in MDA-MB-231 cells
[71]. In agreement with our results that loss of HIFα
function, rather than hypoxic exposure, impacts ITGA6
transcription, the authors of this study did not report
any hypoxia-dependent differences in ITGA6 mRNA
levels. Changes in ECM stiffness are also implicated in
promoting breast tumor invasion through the integrins
[72]. In fact, in normal mammary epithelial cells, in-
creasing ECM stiffness is sufficient to induce malignant
phenotypes, which are sensed in part through a α6ß4,
Rac1 and PI3K signaling pathway [73]. Hypoxic expos-
ure is one of many stressors that increase cell stiffness
[74]. Hypoxia-induced matrix stiffening can stimulate
cell motility [75]. The level of ITGA6 protein was also
recently found to increase in myofibroblast cells in re-
sponse to increased stiffening of a polyacrylamide matrix
[76].
In summary, CD49f enrichment is likely to enhance
multiple cell motility and cell signaling outputs that
crosstalk to promote malignancy and metastatic
phenotypes, including CSC-like behaviors. The relation-
ship between high levels of HIFα protein and increased
expression of HIF transcriptional targets, including
ITGA6, in basal breast cancers likely directly contributes
to their enhanced aggressive nature, including the en-
hanced risk of relapse within the first five years of diag-
nosis [77]. Future studies employing genetic modulation
of ITGA6 levels may be useful in identifying druggable
targets downstream of ITGA6 to block metastasis.
Conclusions
We identify ITGA6 as a novel HIF-dependent target
gene that controls stem-like cell phenotypes and tumor
cell invasion in pre-clinical models of metastatic breast
cancer. Enrichment for CD49f in breast cancer cells also
enriches for HIF-1α expression and expression of down-
stream HIF target genes. Thus, our data suggest that
HIF-dependent regulation of the ITGA6 gene is one
mechanism by which sorting for CD49f + cells enhances
CSC and metastatic phenotypes in breast cancers since
HIF-1 activity is highest in CD49fHigh cells. These rela-
tionships are particularly relevant to basal-like breast
cancers which express higher levels of HIF-dependent
target genes and ITGA6 relative to the other common
molecular subtypes.
Methods
Animals
MMTV-PyMT+ transgenic mice (FVB/Nj strain) were
generously provided by Dr. Kent Hunter (National Can-
cer Institute). FVB/Nj female mice were purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). All ani-
mal procedures were approved by the Institutional Ani-
mal Care and Use Committee at the University of
Tennessee Health Science Center in Memphis, TN
(UTHSC).
Cell culture
PyMT+ HIF-1 WT and KO cells were generated and
propagated in cell culture as described in [3]. MDA-MB-
231 or MCF-7 cells in which HIF1A (shHIF1A), HIF2A
(shHIF2A) or both genes (shHIF1A/shHIF2A) were sta-
bly knocked down by shRNA targeting were generated
using pLKO.1-based lentiviruses in the Wenger labora-
tory, and validated for knockdown efficiency in [38].
Cells transduced with empty vector virus (pLKO.1-puro)
were used as controls (shControl). All MDA-MB-231
cell lines and tumors xenografted in immunocomprom-
ised mice were previously generated and characterized
in [36]. MDA-MB-231 cells and MCF-7 cells were au-
thenticated by DDC Medical (Fairfield, OH) and a
search of the short tandem repeat (STR) database hosted
by ATCC. All human cell lines were grown in DMEM-
Hi, supplemented with 10 % FBS, 1× antimycotic-
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antibiotic (AA) (Sigma, St Louis, MO, USA), 25 mM
HEPES and shRNA selection antibiotics as in [36, 38].
Cells were routinely screened for mycoplasma using the
MycoAlert kit (Lonza, Basel, Switzerland).
Antibodies
All antibodies and dilutions used in experiments are
listed in Additional file 7: Table S1.
Flow cytometry and cell sorting
Cells grown in monolayer were detached with 0.25 %
trypsin/EDTA and washed several times with HBSS prior
to resuspension in flow buffer (HBSS containing 2 %
FBS, 10 mM HEPES, and 1 mg/ml DNase I). Cell num-
ber and viability were verified by trypan blue staining
prior to antibody staining. All cultured cells (1 × 106 in
200 μl flow buffer) were stained on ice for 1 h with
CD49f-FITC (cat#555735, BD Biosciences, San Jose,
CA). PyMT cells were also co-stained with CD24-PE
(cat#553262). Samples were rinsed once with 2 ml flow
buffer, pelleted and kept on ice until analysis at the
UTHSC Flow Cytometry core on a LSR II flow cyt-
ometer. All raw data were exported from FACSDiva soft-
ware and analyzed using FlowJo v8.8.7 software (Tree
Star, Ashland, OR). For each genotype of cells, a repre-
sentative plot of the percentage of CD49f-FITC+ cells
(red histogram) relative to the corresponding isotype
control (blue histogram) is shown.
FACS analysis of PyMT HIF-1 WT or KO tumors was
performed as follows. HIF-1 WT or KO tumors were de-
rived from HIF-1 WT and KO MTECs transplanted into
the right inguinal mammary fat pad of 3-week old FVB/
Nj female recipients (50,000 cells input) as in [3]. Late
stage tumors (350–750 mm3 volume) were minced to a
fine paste and digested with collagenase type III
(Worthington Biochemical Corp, Lakewood, NJ, USA).
Single cells from tumors (40 × 106 cells total) were
subjected to immunostaining using CD49f and CD24
antibodies. Tumor cells were also stained with the
biotin-conjugated mouse lineage panel (cat#559971) and
CD31-biotin (cat#553371), followed by streptavidin
(SA)-APC (cat#554067) to facilitate gating against
hematopoietic lineage (Lin)-positive cells and/or endo-
thelial cells present in whole tumors. Cells were rinsed
with flow buffer and then sorted for purity using the
100 μm nozzle on a FACSAria Cell Sorter (BD Biosci-
ences) using the gating strategy described in [3] and also
presented in Additional file 4: Figure S4.
After exclusion of dead cells and doublets, PyMT
tumor cells were sorted for two cell populations: CD49f
+/CD24High or CD49fNeg/CD24Low, whereas MDA-MB-
231 cells were sorted only for CD49fHigh or CD49fLow as
these cells are negative for CD24 [15]. The gating strat-
egy for CD49f-FITC sorting of MDA-MB-231 cells is
presented in Additional file 6: Figure S6. Mock-sorted
MDA-MB-231 or PyMT cells were exposed to primary
antibodies, but no gates were applied during sorting. All
sorted cells were collected into 4.5 ml tubes pre-coated
with FBS and filled with 1 ml of DMEM containing 20 %
FBS. Post-sort analysis was performed to verify purity
and viability (by 7-AAD) of sorted populations. Cell via-
bility was re-confirmed in the laboratory by trypan blue
staining and hemacytometer analysis just prior to down-
stream assays.
Immunofluorescence (IF)
PyMT+ HIF-1 WT and KO tumor cells were plated onto
tissue-cultured treated, chamber-well slides in standard
culture media. At 80 % confluence, cells were placed at
normoxia or hypoxia (0.5 % O2) for 6 additional hours.
Slides were fixed with 4 % paraformaldehyde for 20 min
at room temperature followed by immunostaining with
anti-CD49f-FITC (1:50, BD Biosciences). For MDA-MB-
231 cells, trypsinized cells were stained in suspension in
FACS buffer at a dilution of 1:50 CD49f-FITC, washed,
counterstained with Hoechst 33342, and cytospun onto
glass slides. For MDA-MB-231 sorted cells, each cell
population (Mock, CD49fHigh or CD49fLow) was cytos-
pun onto glass slides and fixed with methanol for
20 min. FITC-signal was allowed to fade for 7 days, then
slides were re-stained with anti-CD49f-FITC and anti-
HIF-1α antibodies, followed by counterstaining with
DAPI. All slides were mounted in SlowFade mounting
medium and digitally imaged on a Zeiss LSM700 con-
focal microscope using identical capture times and set-
tings. Un-manipulated raw (.tiff ) images are presented.
Gene expression
Total RNA was extracted from PyMT or MDA-MB-231
parental cultured cells, or Mock-sorted, CD49fHigh or
CD49fLow MDA-MB-231 cell populations sorted from
shControl cells, or from pulverized whole tumors using
RNABee (Tel-Test, Friendswood, TX). RNA integrity
was assessed by the Agilent 2100 Bioanalyzer (Santa
Clara, CA, USA) at the UTHSC Molecular Resource
Center. Total RNA was transcribed into cDNA using the
High-Capacity cDNA reverse Transcription kit (Applied
Biosystems, Foster City, CA, USA). Optimized primer
and probe sets were designed with the Roche Universal
Probe Library assay Design Center software (Roche Ap-
plied Science, Indianapolis, IN). Ints3 (integrator com-
plex subunit 3) or PPIA (cyclophilin A) were used as a
loading control for murine or human samples, respect-
ively. The advanced relative quantification algorithm or
the relative expression quantification algorithm of the
Roche LightCycler 480 system was used to calculate
gene expression relative to the loading control. Analysis
of expression of HIF target genes in MDA-MB-231
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sorted cells (PHD3, CAR9, WISP2) was performed using
LightCycler 480 SYBR Green master mix and the relative
expression comparison method after normalization to
cyclophilin A (PPIA), using the primers reported in [38].
Primer sequences/probes are provided in Additional file
7: Tables S2–S3.
Promoter analysis and chromatin immunoprecipitation
(ChIP) assays
The Itga6 and ITGA6 proximal promoters (−2000 to
+500 bp) were scanned for the presence of putative
functional hypoxia response elements (HREs) using the
Transcription Factor Matrix (TFM) Explorer algorithm
applying weight matrices available from JASPAR and
TRANSFAC. Primers were designed to three independ-
ent HREs in the ITGA6 promoter, or the one HRE site
in the Itga6 (murine) promoter, as well as to non-HRE
sequences (Additional file 7: Table S4). MDA-MB-231
shControl or shHIF1A transduced cells were cultured at
21 % (normoxia) or 0.5 % O2 (hypoxia) for 6 h and fixed
with 1 % formaldehyde for 12 min. DNA was sheared to
~500 bp fragments by sonication using a Diagenode
Bioruptor™ set to high, with a 30 s burst followed by
30 s cooling for 10 min. ChIP was performed using pri-
mary antibodies against HIF-1α, HIF-2 α or rabbit IgG,
the control for non-specific antibody binding. Antibodies
were incubated with protein A agarose beads and
sheared DNA overnight at 4 °C, washed and eluted in
100 μl elution buffer (1 % SDS plus 0.1 M NaHCO3). Re-
verse crosslinking was accomplished by adding 1 μl of
10 mg/ml RNase and 5 M NaCl to a final concentration
of 0.2 M and incubation at 65 °C for 5 h, followed by di-
gestion with Proteinase K at 37 °C for 1 h. Immunopre-
cipitated DNA was recovered using the ChIP DNA
Clean and Concentrator kit (Zymo Research, Irvine,
CA). qRT-PCR was performed on all samples using
LightCycler 480 SYBR Green master mix. Input DNA
(non-IP enriched) values were used to normalize each
ChIP DNA fraction’s Cp (crossing point) value to the in-
put DNA fraction Cp value to account for chromatin
sample preparation differences (ΔCpNormalized ChIP). The
normalized ChIP fraction Cp values were then adjusted
based on the normalized IgG only IP fraction Cp value
(ΔΔCp = (ΔCpNormalized ChIP - (ΔCpNormalized IgG). The
ChIP assay site fold enrichment above the sample spe-
cific background was then calculated as 2(−ΔΔCp). Previ-
ously validated HRE sites present in the erythropoietin
(EPO) 3’ UTR or the Vegf proximal promoter amplicons
were used as a positive control. The sequences of the
primers that span HRE regions are listed in Additional
file 7: Table S4. Data are presented as the mean site fold
enrichment ± SEM after correction for input and the
IgG control for each genotype of cells (shControl vs.
shHIF1A), and are representative of three independent
experiments.
Luciferase reporter assay
A commercial ITGA6 luciferase reporter construct was
purchased from SwitchGear Genomics (catalog number
S708174). The HRE site contained within this fragment
was mutated to generate a ITGA6 (mutant)-Luc reporter
using the Phusion Site-Directed Mutagenesis Kit (Thermo
Scientific) and the following 5’-phosphorylated primers:
Forward 5’-GGGGCTCCCACGTaaTaGCTTCCGGGC-3’
and Reverse 5’-GGAGGCGAGCTCGCGGCG AAG -3’.
MDA-MB-231 shControl or shHIF1A/shHIF2A cells were
transfected with the WT or mutant ITAG6-Luc reporter
and with or without a plasmid expressing a stabilized ver-
sion of murine HIF-1α: pcDNA3 mHIF-1α MYC-tag
P402A/P577A/N813A (AddGene 44028) using Lipofecta-
mine 2000 (Life Technologies) according to the manufac-
turer instructions. Forty-eight hours post-transfection, the
transfected cells were exposure to hypoxia (0.5 % O2) for
6 h. Luciferase activities were measured from lysed cells
using the Dual-Luciferase Reporter Assay System (Pro-
mega) and normalized to protein concentrations. Relative
luciferase activities were calculated by setting the lucifer-
ase activity in control cells (shControl cells at normoxia
not transfected with mHIF-1α set to 1.0). Data presented
are representative of three independent experiments.
Limiting dilution transplantation and lung metastasis
assays using sorted PyMT tumor cells
Four cell inputs (25, 50, 100 or 200 cells) per sorted
population (CD49f+/CD24High or CD49fNeg/CD24Low)
were injected into the cleared mammary fat pads of 3-
wk old FVB/Nj recipients (n ≥6 mice/cohort) in a
volume of 10 μl of 1:1 HBSS: growth-factor reduced
Matrigel (BD Biosciences, San Jose, CA). Mice were pal-
pated 1-2×/week and tumors measured with digital cali-
pers. Lesions were scored positive for tumor initiation
when the diameter of the lesion was ≥ 5 mm in diameter.
Data was input into the Extreme Limiting Dilution Ana-
lysis (ELDA) software for estimation of TIC frequency,
as in [3]. In a subset of mice, tumors were allowed to
grow to a size of 500 mm3 and the animals were sacri-
ficed to harvest lungs and to compare the mean of lung
metastases per population among cohorts as scored by
evaluating H&E-stained paraffin sections as in [3].
Tumorsphere assay
Single cells derived from digested PyMT+ tumors were
FACS-sorted based on the expression of CD49f and
CD24 into two populations: CD49f+/CD24High and
CD49fNeg/CD24Low. Sorted cells from each population
were immediately plated post-sorting at a density of 15
cells/μl into ultra low adhesion tissue culture plates
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(Corning, NY, USA) containing tumorsphere medium
and the sphere formation efficiency (SFE) calculated as
in [3].
Invasion assays
MDA-MB-231 cells were serum-starved overnight prior
to plating in invasion assays. Trypsinized cells were
plated into the upper chamber of control (8 μm pore) or
Matrigel-coated Transwell inserts (BD Biosciences) con-
taining serum-free DMEM-Hi medium at a density of
10,000 cells/well and attracted to medium containing
10 % FBS. Cells were allowed to migrate/invade for 24 h
at normoxia or hypoxia (0.5 % O2) (n ≥ 3 wells per
genotype per condition). To compare invasion of
CD49f-FITC-sorted populations, cells were collected
post-sorting into serum-coated FACS tubes as described
above, washed once with PBS and then allowed to re-
cover from sorting overnight at 4 °C in tumorsphere
stem cell media, as in [3]. Cells were then plated at a
density of 30,000−50,000 cells/well and exposed to hyp-
oxia (0.5 % O2) for 24 to 48 h (n ≥3 wells/population/ex-
periment). Crystal violet stained filters were imaged
using ImageJ software and the invasion index calculated
following correction for random migration per manufac-
turer's instructions.
ITGA6 siRNA knockdown and ectopic ITGA6 expression
To determine whether ITGA6 is necessary for invasion in
MDA-MB-231 cells, cells were transiently transfected with
Lipofectamine 3000 at 50 % confluence to 100nM of a pool
of siRNAs targeting ITGA6 (Dharmacon, SMARTpool,
catalog number L-007214) or to a siRNA GFP control de-
scribed in [78] for 18 h. The next day, cells were exposed
to complete growth medium for 8 h, then serum-starved
overnight (20–22 h), then prepared the next day for inva-
sion assays as described above. Data shown is the grand
mean ± SEM of three independent experiments. For ec-
topic expression of ITGA6, a pcDNA3.1 plasmid express-
ing ITGA6 transcript variant 2 (NM_000210; GenEZ ORF
clone: OHu24858, GenScript, Piscataway, NJ) was trans-
fected by Lipofectamine 3000 into shHIF1A/shHIF2A
MDA-MB-231 cells and a stable cell line was created by se-
lection with neomycin (G418, 1200 ng/ml). Invasion was
compared relative to shControl cells transfected with
pcDNA3.1-neo empty vector and to parental shHIF1A/
shHIF2A MDA-MB-231 cells. Data shown is the grand
mean ± SEM of three independent experiments.
Breast tumor subtype analysis and correlation with
survival
Relative ITGA6 expression among PAM50-classified sub-
types was based on normalized data downloaded from
The Cancer Genome Atlas (TCGA) website [30]. p-values
were calculated by ANOVA with Bonferroni correction.
Correlation between HIF1A or HIF2A and ITGA6 mRNA
expression was also analyzed using TCGA data. Correla-
tions between ITGA6 expression and survival were de-
rived using the Gene Expression Omnibus [GEO:
GSE1992] data set [42]. Normalized ITGA6 expression
values were divided into four equal quartiles based on dis-
tribution frequencies. Thirty-seven tumors were included
in the top quartile (≥75 % percentile) defining “high”
ITGA6 expression (≥0.484), and 45 tumors were included
in in the lowest quartile (≤25 % percentile), defining “low”
ITGA6 expression (≤ −0.813). Survival analyses were per-
formed using Prism 5.0 (GraphPad, San Diego, CA) and
p-values calculated by the log-rank test.
Additional files
Additional file 1: Figure S1. Expression of HIF-1α and HIF-2α in MDA-
MB-231 shRNA cells. A-B. qRT-PCR was performed to evaluate changes in
HIF1A (B) or HIF2A (C) mRNA levels in all 4 genotypes of MDA-MB-231 cells
when cultured at 0, 6 or 24 hours of hypoxia (0.5% O2). The mean ± SEM
relative expression (exp.) of HIF1A or HIF2A to PPIA (cyclophilin A) is shown
(n=3 biological experiments). *p-value <0.05 by two-way ANOVA; n.s. equals
not significant. C. Western blotting of high-salt enriched, whole cell extracts
prepared as in [3] to detect HIF-1α and HIF-2 α proteins in all 4 genotypes
of MDA-MB-231 cells cultured at normoxia (N) or hypoxia (H; 0.5 % O2, 24h).
TBP is included as a loading control. (JPG 432 KB)
Additional file 2: Figure S2. A decrease in CD49f+ cells is conserved
in HIF shHIF1A/shHIF2A MCF-7 cells. Similar to MDA-MB-231 cells, the
percentage of luminal, ER+ MCF-7 HIF shHIF1A/shHIF2A cells that ex-
press CD49f is reduced as compared to shControl cells (data shown is
representative of three independent experiments). (JPG 225 KB)
Additional file 3: Figure S3. ChIP data at the -1333 HRE site and
additional ChIP assay controls. A. Less than a 50% site fold enrichment was
observed at the -1333 putative HRE site as compared with shHIF1A MDA-
MB-231 cells. B. ChIP assay controls for MDA-MB-231 cells following IP with
(anti-rabbit IgG) antibodies or IP with HIF-1α or HIF-2α at a non-HRE site
present in the ITGA6 promoter. All data represent the mean fold-change ±
SEM for technical replicates, and are representative of three independent ex-
periments. C. Deletion of Hif1a in PyMT tumor cells exposed to hypoxia for
6 hours reduces enrichment of HIF-1α binding at an HRE located at -1690 in
the Itga6 promoter. As a positive control, HIF-1α binding to a
previously characterized functional HRE in the murine Vegf promoter was
included [79]. All primers and genomic sequence information are reviewed
in Additional file 7: Table S4. (JPG 401 KB)
Additional file 4: Figure S4. Representative gating strategy and post-sort
analysis of mammary tumor cells isolated from MMTV-PyMT+ transgenic
mice. Late stage carcinomas derived from MMTV-PyMT+ transgenic
female mice were digested to obtain single tumor cells, which were
stained with CD49f-FITC, CD24-PE, anti-mouse CD31-biotin and the
anti-mouse biotin-conjugated lineage (Lin) panel, detected by SA-
APC, and sorted on a BD Biosciences FACSAria cell sorter as in [3].
After gating for cell viability (against 7-AAD+ cells), singlets were
enriched based on forward scatter (FSC) profiles, followed by gating
against APC+ cells (Lin+ and/or CD31+). Two populations of cells were
then collected in a two-way sort: CD49f+/CD24High vs. CD49fNeg/CD24Low.
(JPG 535 KB)
Additional file 5: Figure S5. Manipulation of ITGA6 expression levels
by siRNA knockdown and ectopic expression. (A) (Left) Validation of
siRNA knockdown of ITGA6 protein levels in shControl MDA-MB-231 cells
following treatment with siRNA; cells exposed to siRNA to GFP are shown
as the control. TBP is shown as a loading control. (Right) The levels of
ITGA6 mRNA decrease approximately 10-fold following transfection with
the ITGA6 siRNA SMARTpool. (B) ITGA6 protein expression was compared by
western blotting of shControl, shHIF1A/shHIF2A cells and shHIF1A/shHIF2A
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cells reconstituted with ectopic ITGA6. After correcting for loading based on
TBP expression, there was a 37 % percent increase in ITGA6 levels in the
shHIF1A/shHIF2A context (quantitated by ImageJ software). (JPG 353 KB)
Additional file 6: Figure S6. Representative gating strategy and post-
sort analysis of MDA-MB-231 cells sorted by CD49f. shControl cells were
cultured to ~80 % confluence and harvested by trypsin-EDTA to prepare
single cells for CD49f-FITC staining. Viable cells were gated based on FSC-A
vs. SSC-A, followed by gating for singlet events. Gates for CD49f-FITC positive
or negative cells were based on the anti-rat isotype antibody control. Two
populations of cells were then collected in a two-way sort based on purity,
gating for the lowest and the highest (~20–25 % upper or lower) of CD49f-
expressing cells: CD49fHigh vs. CD49f Low. Sort purity and viability (by 7-AAD
staining) were confirmed in each sorted population. (JPG 523 KB)
Additional file 7: Table S1-S4. Tables related to reagents and primers
used in the Methods. (DOCX 24 kb)
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Additional file 7 Tables related to reagents and primers used in the Methods.  
Additional Table S1 Antibody source and dilution factors for reagents utilized in FACS analysis, 
western blotting, ChIP and IF staining assays. 
 
 
Antibody Source (Catalog #) Dilution Purpose 
anti-mouse/human 
CD49f-FITC  BD Biosciences (555735) 
1:200 
1:50 
FACS  
IF 
anti-mouse CD31-
biotin BD Biosciences (553371) 1:200 
FACS 
PyMT cells 
anti-mouse CD24-PE BD Biosciences (553262) 1:200 
FACS 
PyMT cells 
anti-mouse lineage 
panel-biotin BD Biosciences (559971) 1:200 
FACS 
PyMT cells 
SA-APC BD Biosciences (554067) 1:200 
FACS 
PyMT cells 
anti-HIF-1α Abcam (ab2185) 
1:500 
1:150 
IF 
ChIP, mouse 
cells 
Anti-ITGA6 (α6; 
rabbit monoclonal) 
Life Technologies, Novex 
(701178) 1:250 western blot 
Anti-TBP Abcam (ab818) 1:2,000 western blot 
anti-HIF-1α Santa Cruz (sc-10790X) 1:150 
ChIP, human 
cells 
anti-HIF-2α Novus Biologicals (100-122) 1:150 ChIP 
anti-rabbit IgG Cell Signaling (7074P2) 1:250 ChIP 
 
Additional Table S2 Primers and Roche Universal Probe Library (UPL) FAM-labeled probes utilized in 
primer and probed-based real-time PCR assays. All assays were designed using the Roche Universal 
ProbeLibrary Assay Design Center website (http://qpcr.probefinder.com/organism.jsp). 
 
 
Gene Symbol NCBI Accession Forward Primer Reverse Primer UPL ID 
Itga6  NM_008397 attcaggagtagcttggtggat ttctcttgaagaagccacacttc 79 
Ints3 NM_145540 gtggctgttattgactctgcac caggttccccatcatcacat 17 
ITGA6A or B 
(gene expression 
assay) NM_000210 tttgaagatgggccttatgaa ccctgagtccaaagaaaaacc 22 
ITGA6A or B  
(confirm siRNA 
knockdown) NM_000210 Agcctcttcggcttctcg ttggctctctgcagtggaa 29 
PPIA 
(cyclophilin A) NM_021130 atgctggacccaacacaaat tctttcactttgccaaacacc 48 
 
 
  
 2 
Additional Table S3 Primers used in SYBR green qRT-PCR reactions to detect human genes. 
 
Gene Symbol NBCI Accession Forward Primer Reverse Primer 
HIF1A NM_001530 tccgatggaagcactagaca tggtgacaactgatcgaagg 
PPIA NM_021130 atgctggacccaacacaaat tctttcactttgccaaacacc 
ITGA6A or B NM_000210 tttgaagatgggccttatgaa ccctgagtccaaagaaaaacc 
PHD3 NM_022073 atcgacaggctggtcctcta cttggcatcccaattcttgt 
CAR9 NM_001216 gggtgtcatctggactgtgtt cttctgtgctgccttctcatc 
WISP2 NM_003881 ctcctctgcctcctctcaaa gtctccccttcccgatacag 
 
Additional Table S4 Primers used in ChIP assays in human MDA-MB-231 and murine PyMT tumor 
cells. 
 
 
Genomic 
Region 
Sequence  
Accession  ChIP Antibody Forward Primer Reverse Primer 
-170; ITGA6 NM_00210 HIF-1α or HIF-2α ctccctcgctctgtgctact gtctccagctgcccggta 
-1333; ITGA6  HIF-1α acagctcctgctctttcctg agaaccccatggttttcagc 
-1762; ITGA6  HIF-1α or HIF-2α ggaccccatctctctggat tgattttggagagcacacagtt 
-2150; non-
HRE ITGA6  HIF-1α or HIF-2α gggaagacaggaatcaatgg tcacaacctggcaaatgaaa 
-1690; Itga6 NM_008397 HIF-1α ccagggcaagatgtgagatt acccaaagcgtccttctaca 
-1100; non-
HRE Itga6  HIF-1α caactgtaatttgaaacatctgcaa tcctctgacatttagattagcatgttt 
EPO HRE, 
3’UTR NM_000799 HIF-1α or HIF-2α gctggcctctggctctcatgg cagggttggcagctgccttactg 
Vegfa, promoter NM_009505 HIF-1α ctggcttcagttccctggcaacatctct cctggggtgaatgggatcctctgg 
 
 
 
  
